Requirements for Standardized Study Data: Update on Guidance Ron Fitzmartin, PhD, MBA Data Standards Program Office of Strategic Programs Center for Drug.

Slides:



Advertisements
Similar presentations
Principal Statistical Programmer Accovion GmbH, Marburg, Germany
Advertisements

U.S. Food and Drug Administration
SEND Standard for the Exchange of Nonclinical Data
Development of Guidance Documents Jennifer Scharpf, M. P. H
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development IND Regulatory.
“Paperless Labeling Rule” Proposed Rule First Look January 2015.
Recently Issued OHRP Documents: Guidance on Subject Withdrawal and Draft Revised FWA Secretary’s Advisory Committee on Human Research Protections October.
Introduction to Regulation
CFR Index, Thesaurus of Indexing Terms, and Agency List of Subjects
CBER Blood Establishment Registration and Product Listing Jan O’Brien Blood Registration Coordinator DBA, OBRR, CBER September 15, 2009.
Standardized Study Data: An Update Presented at the DCDISC Meeting Ron Fitzmartin, PhD, MBA Office of Strategic Programs Center for Drug Evaluation and.
1 ACPS November 15, Update Nancy B. Sager, Associate Director Office of Pharmaceutical Science Center for Drug Evaluation & Research Food and.
1 DRUG QUALITY SYSTEM FOR THE 21 ST CENTURY PQRI/FDA April CHANGES WITHOUT PRIOR APPROVAL AN FDA PERSPECTIVE Dennis M. Bensley, Jr., Ph.D. Center.
Bay Area CDISC Implmentation Network – July 13, 2009 How a New CDISC Domain is Made Carey Smoak Team Leader CDISC SDTM Device Team.
Beyond regulatory submission - Standards Metadata Management Kevin Lee CDISC NJ Meeting at 06/17/2015 We help our Clients deliver better outcomes, so.
DRAFT Guidance for Industry: Providing Regulatory Submissions in Electronic Format – Drug Establishment Registration and Drug Listing Denise Sánchez, J.D.,
11 February 2008NLM BOR WG on Clinical Trials1 Clinical Trials Registration and Results Reporting: Legislative Requirements Jerry Sheehan Assistant Director.
© 2011 Octagon Research Solutions, Inc. All Rights Reserved. The contents of this document are confidential and proprietary to Octagon Research Solutions,
Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.
HL7 Study Data Standards Project Crystal Allard CDER Office of Computational Science Food and Drug Administration February 13,
Investigational New Drug Application (IND)
ICH V1 An FDA Update Min Chen, M.S., RPh Office of Drug Safety Center for Drug Evaluation and Research FDA January 21, 2003.
Second Annual Japan CDISC Group (JCG) Meeting 28 January 2004 Julie Evans Director, Technical Services.
1 RCRIM Vocab-BRIDG Session Wednesday, Session Q2 19 September 2007.
Dave Iberson-Hurst CDISC VP Technical Strategy
Update from the Office of Generic Drugs Gary J. Buehler, R.Ph. Director, Office of Generic Drugs Center for Drug Evaluation and Research Food & Drug Administration.
1 Combination Products: Jurisdictional Issues MassMEDIC Presentation March 28, 2006 Janice Hogan, Esq. Partner Hogan & Hartson, LLP
WG4: Standards Implementation Issues with CDISC Data Models Data Guide Subteam Summary of Review of Proposed Templates and Next Steps July 23, 2012.
Study Data Reviewer’s Guide (SDRG): Recommendations on Use of the Clinical SDRG Model for Nonclinical Data Submission Nonclinical Working Group, SDRG Project.
Draft Transition Plan for the Transfer of the Drug Medi-Cal Treatment Program Fourth Series: Stakeholder Meetings Department of Health Care Services Department.
Overview of FDA's Regulatory Framework for PET Drugs
CTD Dossier Preparation K. Srikantha Reddy Sr
Labeling and Electronic Initiatives Rachel E. Behrman M.D., M.P.H. Deputy Director, Office of Medical Policy CDER FDA Science Board, April 15, 2005.
FDA ICH Public Meeting 5630 Fishers Lane, Rockville, MD May 8, :30 am -- 2:00 pm Implementation of the CTD Update-Issues-Next Steps Justina A. Molzon,
Update: Medical Device User Fee and Modernization Act of 2002 Blood Products Advisory Committee March 13, 2003 Mary Elizabeth Jacobs, Ph.D. Associate Director.
CDISC – 17/12/2012 Carine Javierre Nathalie SABIN.
October 28, F OOD AND DRUG ADMINISTRATION AMENDMENTS ACT OF 2007 (FDAAA) and Risk Evaluation and Mitigation Strategies (REMS) Presented to the Ninth.
Update on Current FDA Labeling Initiatives Iris P. Masucci, PharmD, BCPS Center for Drug Evaluation and Research FDA November 16, 2006 Pediatric Advisory.
Initiatives Drive Pediatric Drug Development January 30, 2002.
PhUSE Computational Science Working Groups Solutions Through Collaboration.
1 Briefing on the Draft Call for Projects and Schedule for the Air Quality Conformity Assessment for the 2011 CLRP and FY TIP Technical Committee.
Updates on CDISC Activities
German Speaking CDISC UG, 22-Sep CDER Common Data Standards Issues Document Motivation CDISC submissions received varied more than expected Contents.
Pre Award Process for Federal Program Officers Competitive Grants Randi Neff Federal Program Officer.
DIA Electronic Submissions Meeting Olga Alfieri 26 April 2016
How Good is Your SDTM Data? Perspectives from JumpStart Mary Doi, M.D., M.S. Office of Computational Science Office of Translational Sciences Center for.
© Copyright IBM 2007DIA ERS SIAC Presentation, January 2008 The HL7 RPS and SPL Standards - A High Level View Terry Hardin Sr. IT Architect Emerging Software.
Regulated Product Submission Eileen M. Girten, MS i3 Statprobe 1DIA Education SIAC.
DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on the Somatic Cell.
Validation Gary Gensinger Deputy Director Office of Business Process Support Center for Drug Evaluation and Research.
ISO/HL Specification: Individual Case Safety Report (ICSR) Release 2 Lise Stevens Data Standards Project Manager FDA CBER/ADRM Bioinformatics Support.
ClinicalTrials.gov Requirements
ACR Appropriateness Criteria® Feedback and Commenting
FDA Experience with eCTD
Formal Meetings between FDA and Sponsors of PDUFA Products
Beyond regulatory submission - Standards Metadata Management Kevin Lee CDISC NJ Meeting at 06/17/2015 We help our Clients deliver better outcomes, so.
doc.: IEEE <doc#>
Labeling and Electronic Initiatives
SUNY Pre Award and Compliance Systems Institutional Review Board (IRB)
doc.: IEEE <doc#>
Streamlining IRB Procedures for Expanded Access
CAC Meeting Tuesday, 21 June, CAC Meeting Tuesday, 21 June, 2017.
doc.: IEEE <doc#>
doc.: IEEE <doc#>
SDTM and ADaM Implementation FAQ
doc.: IEEE <doc#>
An FDA Statistician’s Perspective on Standardized Data Sets
1915(c) WAIVER REDESIGN 2019 Brain Injury Summit
Data Submissions Douglas Warfield, Ph.D. Technical Lead, eData Team
Presentation transcript:

Requirements for Standardized Study Data: Update on Guidance Ron Fitzmartin, PhD, MBA Data Standards Program Office of Strategic Programs Center for Drug Evaluation & Research Food and Drug Administration Presented at the CSS / PhUSE Meeting Silver Spring, MD 17 March 2014

2 Disclaimer The views and opinions presented here represent those of the speaker and should not be considered to represent advice or guidance on behalf of the Food and Drug Administration.

March, March, 2014

4 Road to Required Electronic Standardized Study Data

6 …no earlier than 24 months after final guidance issued after public notice” [certain] submissions shall be submitted in such electronic format as specified by the Secretary in such guidance. … the [FDA] may—provide a timetable for establishment of further standards for electronic submission as required and set forth criteria for waivers of and exemptions from the requirements. FDASIA Statute* Authorized Required Electronic Submissions *FDASIA: FDA Safety & Innovation Act (2012) CDER CBER

PDUFA V Goals – Section XII 7 “…develop standardized clinical data terminology through open standards development organizations (i.e., CDISC)” “… periodically publish final guidance specifying the completed data standards, formats, and terminologies that sponsors must use to submit data in applications.” FDASIA* Re-Authorized PDUFA V *FDASIA: FDA Safety & Innovation Act (2012)

Re-Designed FDA Web Page 8 Quick access to Catalog, Guidance and Tech Guide

Draft Binding Guidances & Tech Guide 9 Published for Public Comment: 6 February 2014

What is Binding Guidance? 10 Binding Guidance = Recommends, Suggests, Encourages Requires “Please” Do it! Binding Guidance has a bite!

Submission types: –NDAs, ANDAs, Certain BLAs & INDs Submission not in the electronic format(s) specified in guidance will not be filed. Electronic submissions are required no earlier than 24 months after a final guidance is issued. Individual draft guidances will be developed. 11 FDASIA 745A(a) Guidance (1)

Electronic submission of standardized study data required for: –Certain INDs –NDAs –ANDAs –Certain BLAs Including amendments, supplements, and reports 12 eStudy Data Guidance (1)

Study data must be submitted electronically or it will not be filed…unless exempt: –Devices regulated by CBER as biological products under Section 351 of the PHS Act –Study data in noncommercial INDs (e.g., investigator-sponsored INDs, emergency use INDs, and treatment INDs). 13 eStudy Data Guidance (2)

What are the requirements for Standardized Study Data? –Must be in a format that FDA can process, review, and archive. –Formats listed in the Data Standards Catalog (DSC). –DSC lists the supported and/or required standards. –DSC lists key dates for each standard. 14 eStudy Data Guidance (3)

What are the requirements for Standardized Study Data? –DSC lists (or will) dates when: Support begins and ends Requirement begins and ends FDA may Refuse To File –If study data do not conform to the required standards, formats, and terminologies. 15 eStudy Data Guidance (4)

Data Standards Catalog 16 eStudy Data Guidance (5) Dates: Requirement Begins & Ends

Will there be waivers from the requirement? –No. –However, waivers may be granted to use specific (e.g., retired) versions of standards listed in the Data Catalog. 17 eStudy Data Guidance (6)

Initial Timetable for Requirements –NDAs, ANDAs, certain BLA Submissions Studies that start 24 months after publication of final eStudy Guidance. –Start Date defined as by CDISC SDTM Trial Summary Domain Studies must use the standards, formats, terminologies posted in Data Standards Catalog. –Certain IND Submissions Studies that start 36 months after publication of final eStudy Guidance. 18 eStudy Data Guidance (7)

Initial Timetable for Requirement – Example –November 15, Federal Register Notice of final eStudy Guidance #1- Sponsor starts a study October 22, 2016 –Submission of Standardized Study Data not required (but recommended) for that study. #2- Sponsor starts a study December 3, 2016 –Submission of Standardized Study Data will be required for that study. –Must use FDA-supported standards, formats and terminologies specified in the Data Standards Catalog. 19 eStudy Data Guidance (8)

Version Updates –Types Content or structural changes (e.g., new SDTM domains or variables). Typographical errors, corrections, or clarifications. –Federal Register notice will specify the effective date and will correspond to a specific calendar month, e.g., March. –Required in submissions for studies starting no earlier than 12 months after the Federal Register notice. 20 eStudy Data Guidance (9)

Version Updates – Example –May 6, 2016, Federal Register notice - support for new version, SDTM 4.1, and update to the Data Standards Catalog. Effective date posted in the Federal Register notice is March 15, Required in submissions for studies that start after March 15, The Data Standards Catalog will list March 15, 2018 as the “date requirement begins.” 21 eStudy Data Guidance (10)

New Standards –New standards, formats and terminologies Not supported by FDA and Not listed in the Data Standards Catalog when Guidance is final. –After notice in the Federal Register, required in submissions for studies that start 24 months (NDAs, ANDAs, and certain BLAs) and 36 months (for certain INDs). 22 eStudy Data Guidance (11)

Milestone Timetable Example 23 2/6/2014 FY2017 FY2018 5/7/2014 FY2015

Study Data Tech Conformance Guide 24 Guide supplements the eStudy guidance. Provides technical recommendations / specs for e submission of standardized data in INDs, NDAs, ANDAs, and BLAs. Consolidates Common Issues and Study Data Specs + much more.

Study Data Tech Conformance Guide 25

Next Steps eGuidances –Public Comment Period ends May 7 th. –Revise draft documents. –Publish final documents in FY2015. Other Activities –XML Transport Pilot for study data –Testing & Acceptance project for data standards –TA project plan update in FY2014 –TA development – internal and CFAST ongoing 26

Thanks! Ron Fitzmartin 27